Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to -$124.9 million.

  • Amphastar Pharmaceuticals' Cash from Investing Activities rose 43.27% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.4 million, marking a year-over-year increase of 76.37%. This contributed to the annual value of -$124.9 million for FY2024, which is 80.75% up from last year.
  • Amphastar Pharmaceuticals' Cash from Investing Activities amounted to -$124.9 million in FY2024, which was up 80.75% from -$649.1 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Cash from Investing Activities high stood at -$28.7 million for FY2021, and its period low was -$649.1 million during FY2023.
  • For the 3-year period, Amphastar Pharmaceuticals' Cash from Investing Activities averaged around -$268.9 million, with its median value being -$124.9 million (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' Cash from Investing Activities slumped by 1,880.40% in 2023 and then surged by 80.75% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$36.4 million in 2020, then rose by 21.26% to -$28.7 million in 2021, then decreased by 14.32% to -$32.8 million in 2022, then crashed by 1,880.40% to -$649.1 million in 2023, then soared by 80.75% to -$124.9 million in 2024.